Roche (ROG: SIX) majority-owned Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has entered into a license agreement for Noile-Immune Biotech’s proprietary PRIME (proliferation-inducing and migration-enhancing) CAR-T technology.
In recent years, cancer immunotherapy has been widely recognized as a new approach to cancer treatment by enhancing the immune system to attack cancer cells. Chimeric antigen receptor T cell (CAR-T cell) therapy is a type of cancer immunotherapy, in which a patient’s immune cells (T cells) are collected, transfected with a gene for an artificial chimeric antigen receptor (CAR), which recognizes a cancer antigen, expanded in large numbers and returned to the patient’s body.
Noile-Immune Biotech also has a collaboration to develop next generation CAR-T with Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), as well as a deal with US T-cell therapy company Adaptimmune Therapeutics (Nasdaq: ADAP).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze